There are no hidden fees or unexpected charges, and every detail about your investment is explained before you begin treatment
Expect more barriers - prior authorization, documented BMI thresholds, proof of failed lifestyle interventions, or outright exclusion
Semaglutide Injection at $189/mo runs five dose levels weekly (0.25mg to 2.0mg)
Methods The study was designed with one screening round (9 doses over 3 days) of DMSA in Phase 1, followed by a randomized, double-blind, placebo-controlled study of 6 additional rounds (see Figure 1)
Venous Ulcers Cause: Venous hypertension and valve failure poor venous return Typical features: Location: medial gaiter area (ankle/lower leg), rarely toes Appearance: shallow, irregular edges Exudate: often heavy Skin changes: oedema, hyperpigmentation, lipodermatosclerosis Pain: mild to moderate, improves with elevation Management focus: Compression therapy (once arterial disease excluded) Skin care and oedema control Wound dressings to manage exudate Arterial Ulcers Cause: Peripheral arterial disease (reduced blood flow) Typical features: Location: toes, forefoot, heel, pressure points Appearance: punched-out, deep, often necrotic Exudate: minimal Skin changes: cool, pale, shiny, hair loss Pain: severe, worse at night or when leg is elevated Management focus: Urgent vascular assessment Revascularisation where possible Avoid compression until perfusion is confirmed Why this distinction is critical Compression heals venous ulcers but can destroy an ischaemic limb Debridement may be appropriate in venous ulcers but dangerous in arterial disease without blood flow Dressing choice, escalation, and prognosis differ significantly Key message Treating an ulcer without understanding its cause is treating blind
This effect may resolve on its own, but the sudden onset of visual symptoms should always be evaluated, especially in patients with diabetes or a history of eye disease
